By Gabriel Alizaidy, MD, MS
Scientific Director, Maximus
BPC-157 is in the early stages of becoming a household name like Kleenex. Bounty. Vicks. Bandaid.
You probably know at least one person who has healed from a surgery or a beat-up shoulder and has magically rebounded. But it's not all positive stories, for every person who it has healed, someone else runs nearly the same protocol, feels nothing, and decides the whole thing is a scam. How can two people react so differently to a peptide?
Is it because of individual variability? Maybe. Is it because sourcing can be unreliable? Possible. But what if I told you that it is more likely that the environment the peptide is being introduced into is the most likely cause?
What BPC actually does
BPC has a direct effect on tendon fibroblasts, the repair cells in your connective tissue, and on its own it can produce tremendous recovery. It pushes those cells toward the wound, helps them survive oxidative stress, and switches on a signaling complex called FAK-paxillin that lets them physically crawl to the damage (2011). That part runs on its own, no GH needed.
But the results are even better when growth hormone is present in appropriate amounts. BPC raises the number of GH receptors sitting on those same fibroblasts, dose-dependent and time-dependent, at the gene and the protein level (2014). When GH binds those new receptors, an enzyme called JAK2 fires and turns on the genes that build new tissue. More receptors plus more GH means amplified repair.
Why your GH decides the outcome
GH falls after your twenties, and by 50 most people are running on a fraction of what they had, and almost none of them know it (Endotext, Growth Hormone in Aging). So you can have all the upregulated receptors in the world. If there is barely any GH around to bind them, that second half of the mechanism never actually runs. More receptors with no GH to fill them are just doors that lead nowhere.
If your BPC feels underwhelming, the cheapest first move is to check IGF-1. It is a decent proxy for where your GH actually sits. If it comes back low, the fix is upstream of the peptide, and another vial of BPC is not going to solve it.
How to support the GH side
If GH is the bottleneck, the simplest move is a GH secretagogue, a peptide that pushes your own pituitary to release more growth hormone. A few names come up here, tesamorelin, sermorelin, or CJC-1295 stacked with ipamorelin. Of the group, tesamorelin has the strongest human data. It is a GHRH analog, FDA-approved as Egrifta, and in its trials it reliably raised IGF-1 and dropped visceral fat in people (Falutz, NEJM 2007). For someone with confirmed deficiency, exogenous GH is an option too, under real clinical oversight.
But peptides are not the only factor in improving growth hormone levels. Sleep and alcohol both affect your own GH directly. Bad sleep flattens your nighttime GH pulse, and alcohol suppresses GH release outright, so cleaning those up already changes the environment BPC is working in. But if you want to put real signal behind those new receptors, pairing BPC with any growth hormone peptide is the most direct way to do it.
While tesamorelin raising GH and IGF-1 in people is well established, formal trials that pairs BPC with a GH peptide and tracks recovery outcomes has not been run yet. But the mechanism is on solid ground, and practitioners already running this combination in their practice are reporting the kind of results you would expect from the biology.
How we approach peptides at Maximus
This is why guidance matters, and how we think about peptides at Maximus. The goal is to actually understand the pharmacology, the physiology, and the real-world evidence as it accumulates, and use that to build protocols that are up to date, efficient, and based in science. If and when these become available through a compliant pathway, the difference between a good outcome and a wasted one comes down to somebody reading the labs, sequencing the protocol around the person, and tracking whether it is actually working.
BPC-157 can do real work on its own. But if it feels underwhelming, the peptide itself might not be the problem. Check your GH status first via IGF-1, and if it is low, pairing BPC with a GH peptide like tesamorelin is the most direct way to give those receptors something to do. The fix is often upstream of the peptide itself.
----
Disclaimer:
Athlete advisory. BPC-157 and TB-500 are listed as prohibited substances under WADA and USADA. Competitive athletes subject to testing should not use peptides containing them. A licensed provider will discuss this with you during evaluation.
The contents of this article, including, but not limited to, text, graphics, images, and other information, is for information purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. The content is not meant to be complete or exhaustive or to be applicable to any specific individual's medical condition. You should consult a licensed healthcare professional before starting any health protocol and seek the advice of your physician or other medical professional if you have questions or concerns about a medical condition. Always talk to your doctor about the risks and benefits of any treatment. Never disregard or delay seeking professional medical advice or treatment because of something you have read on this site. Maximus does not recommend, endorse, or make any representation about the efficacy, appropriateness, or suitability of any specific test, products, procedures, treatments, services, opinions, healthcare providers or other information contained herein. Maximus is not responsible for, nor will they bear any liability for, the content provided herein or any actions or outcomes resulting from or related to its use.
